A man with advanced HIV presented with verrucous plaques 2-3 months after initial mpox infection. He received two courses of tecovirimat without resolution of initial mpox lesions and development of new lesions raising concern for resistance. He was treated with two doses of brincidofovir and demonstrated improvement 6 months later.
SiegristEASassineJ. Antivirals with activity against mpox: a clinically oriented review. Clin Infect Dis2023; 76: 155–164. 2022/07/30. DOI: 10.1093/cid/ciac622.
2.
FalcinelliFRubegniGRussoF, et al.Not only monkeypox infection: keratoderma blenorrhagicum. Int J STD AIDS2023; 34: 353-354. 2023/01/12. DOI: 10.1177/09564624221149459.
3.
HazraAZuckerJBellE, et al.Mpox in people with past infection or a complete vaccination course: a global case series. Lancet Infect Dis2023. Online ahead of print. 2023/09/08. DOI: 10.1016/s1473-3099(23)00492-9.
4.
ScottiBPiracciniBMGaspariV. Hypertrophic verrucous lesions after monkeypox virus infection. Lancet Infect Dis2022. Online ahead of print. 2022/10/30. DOI: 10.1016/s1473-3099(22)00695-8.
5.
MitjàOAlemanyAMarksM, et al.Mpox in people with advanced HIV infection: a global case series. Lancet2023; 401: 939–949. DOI: 10.1016/s0140-6736(23)00273-8.
6.
AdlerHGouldSHineP, et al.Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis2022; 22: 1153–1162. DOI: 10.1016/s1473-3099(22)00228-6.
7.
FilippovEDuhanSLehmanL, et al.Treatment failure in patient with severe Mpox and untreated HIV, Maryland, USA. Emerg Infect Dis2023; 29: 1262–1265. DOI: 10.3201/eid2906.230059.
8.
SmithTGGCWynnNTMathenyA, et al.Resistance to anti-orthopoxviral drug tecovirimat (TPOXX®) during the 2022 mpox outbreak in the US. Preprint, medRxiv, Epub ahead of print. DOI: 10.1101/2023.05.16.23289856.
